Drawing for HSRX

USPTO serial 77526216

HSRX

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
AYALA, LOURDES
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with HSRX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jennifer L. Whitelaw

JENNIFER L. WHITELAW WHITELAW LEGAL GROUP3838 TAMIAMI TRL N FL 3NAPLES, FL 34103-3590UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Botanical herbal extracts for use in making cosmetics; botanical extracts for use in the manufacture of nutraceuticals and pharmaceuticals; chemical extracts and active principles extracted from medicinal plants for use in the manufacture of nutraceuticals and pharmaceuticals, namely, chemical agents made from botanical extracts; chemical extracts and active principles extracted from medicinal plants for use in the pharmaceutical industry, namely, chemical agents made from botanical extracts or association of chemical extracts for use in the manufacture of pharmaceutical or nutraceutical products; botanical extracts for use in the manufacture of medicated preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, lozenges, inhalers, tincture, suppositories and ampule for injection; botanical extracts used in the manufacture of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection; botanicals and botanical blends, herbals and herbal blends, botanical extracts and botanical extract blends, flavor extracts and flavor extract blends, algal extracts and algal extract blends, all for use in the manufacture of nutritional supplements and vitamins; algal extracts or algal extract blends for use in the manufacture of nutritional and dietary supplements; mushroom, fungus, and spore extracts for use in food manufactureACTIVE—
005Nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; herbal extracts and blends used as an integral ingredient in medicinal foods or beverages; botanical extracts and blends used as an integral ingredient in medicinal foods or beverages; nutritional supplements; herbal products, namely, medicated skin and lip balms; medicated herbal products, namely, ointments, oils, drinks, infusions, syrups, herbal extracts, poisons, tinctures for medical use in the treatment of strokes, infarcts and other cardiovascular and cerebrum diseases; herbal products, namely, mentholated ointments for medical use; oils, namely, fish extract oils for nutritional purposes, nutritional oils not for cosmetic purposes, vitamin oils for human consumption; drinks, namely, meal replacement drinks; dietary supplement drinks, medicinal drinks, and fish oil for use as a dietary supplement and as a nutraceutical dietary supplement; syrups, namely, cough syrups; herbal products for medicinal purposes, namely, herbal extracts for use as nutritional and dietary supplements; herbal products for medicinal purposes, namely, herbal extracts and syrups; medicinal herb extracts; medicinal herb extracts for medical purposes; plant extracts for medical, nutritional, pharmaceutical or veterinary purposes; medicinal herb extracts used in preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, lozenges, inhalers, tincture, suppositories and ampule for injection; medicinal herbal extracts used as component ingredients of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection; botanical extracts used as component ingredients of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection used to treat skin ailments, for infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, inflammatory, cancer and related conditions; yeast extracts for medical, nutraceutical or pharmaceutical purposes; herbal products, namely, herbal powders for nutritional purposes; herbal products, namely, herbal meal replacement powders for dietary and nutritional purposes; herbal products, namely, aromatherapy packs containing herbs used for relief from headaches, insomnia and sinus discomfort; herbal products, namely, herbal powders sold as an integral ingredient of nutritional supplement drink mixes for nutritional purposes; pharmaceuticals and nutraceuticals, namely, vitamins and food supplements; pharmaceutical preparations, namely, appetite suppressants and lipid lowering agents; food for diabetics, infants and enteral feeding; botanical extracts for nutritional use; botanical extracts for nutraceuticals, nutritional use, and pharmaceuticals; botanical extracts for medical, veterinary, nutraceutical and pharmaceutical purposes; designer extracts, namely, herbal extracts for medical, veterinary and pharmaceutical purposes; botanicals and botanical blends, herbals and herbal blends, botanical extracts and botanical extract blends, flavor extracts and flavor extract blends, all sold as components of nutritional supplements and vitamins; nutritional oils not for cosmetic purposes; food supplements, namely, lipid concentrates for use as a dietary food supplement or for pharmaceutical or medicinal purposes; food supplements, namely, anti-oxidants; food for medically restricted diets; dietary supplements, namely, vitamins and mineral supplements; anti-cough drops; cough drops; cough expectorants; throat lozenges; cough lozenges; cough syrups; cough treatment preparations; cold sore treatment preparations; pharmaceutical antitussive-cold preparations; preparations for treating colds; analgesic preparations; analgesics; antipyretic analgesics; ibuprofen for use as an oral analgesic; multipurpose medicated antibiotic cream, analgesic balm and mentholated salve; oral analgesics; topical analgesics; pharmaceutical preparations for the treatment and prevention of herpes; vaccines for the treatment and prevention of herpes; medical biological preparations for the treatment and prevention of herpes; pharmaceutical preparations for the treatment of herpes simplex infection; pharmaceutical capsules for the treatment of herpes simplex infection; homeopathic preparations for the treatment of herpes and cold sores; pharmaceutical preparations for the treatment of herpes viruses; medicated topical clear fluoride gel for the treatment of herpes virus during the physical manifestation of the virus; pharmaceutical preparations for the treatment of herpes simplex virus type I or type ii or herpes zoster virus, not in intravenous form; plant based antivirals; over-the-counter topical antivirals; pharmaceutical preparation with antiviral and/or antimicrobial properties for use in the treatment of herpetic keratitis, conjunctivitis, hiv retinopathy, viral influenza "flu", herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus "herpes zoster" "shingles", cytomegalovirus, viral parainfluenza, adenovirus, viral encephalitis, viral meningitis, arbovirus, arenavirus, picornavirus, coronavirus, syntialvirus, viral infections, common colds caused by viruses, cold sores, human immunedeficiency virus "hiv", roseola infantum, human herpes iv; pharmaceutical preparations for the treatment of viral diseases and disorders, namely, herpes; pharmaceutical preparations for treating immune diseases induced by virus, namely, herpes, herpes zoster and aids; functional foods, namely, dietetic foods adapted for medical purposes, food for diabetics, infants and enteral feeding, food for medically restricted diets; functional beverages, namely, nutritionally fortified beverages; medicinal foods, namely, processed food for medical purposes; animal health products, namely, animal feed supplements, medicated animal feed, micro-nutrient animal feed, dietary supplements for animals, non-medicated additives for animal feed for use as nutritional supplements, nutritional drinks for animals, pharmaceutical preparations for animal skincare; botanical extracts for medical, veterinary and pharmaceutical purposes; herbal extracts for medical, veterinary and pharmaceutical purposes; designer extracts, namely, plant, herbal and botanical extracts for medical, veterinary and pharmaceutical purposes; biodefense products, namely, medicinal preparations for the treatment of infectious diseases and adverse human health conditions, namely, infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, inflammatory, cancer and related conditions; nutritionally fortified beverages for immune enhancement; nutritionally fortified beverages with rice bran and wheat bran; algal products for medicinal purposes, namely, algal extracts or algal extract blends for use as nutritional and dietary supplements; algal products, namely, algal powders sold as an integral ingredient of nutritional supplement drink mix for nutritional purposes; algal products, namely, algal powders for nutritional purposes; algal extracts or algal extract blends for medical or pharmaceutical purposesACTIVE—
042Product research and development; scientific research and development; research and development in the field of biodefense related to pharmaceutical preparations, vaccines, and medicines; chemical and biological research and analysis in the field of identification of chemical components in pharmaceuticalsACTIVE—
045Intellectual property licensingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Apr 12, 2010MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 12, 2010ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 8, 2009NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Jun 16, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 27, 2009NPUBNOTICE OF PUBLICATION—
May 12, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 6, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 5, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 5, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 4, 2009ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 30, 2009GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
Apr 30, 2009GNCFCONTINUATION OF FINAL REFUSAL E-MAILED—
Apr 30, 2009CNCFACTION CONTINUING A FINAL - COMPLETED—
Apr 28, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 28, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 27, 2009ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Apr 13, 2009GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Apr 13, 2009GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Apr 13, 2009CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Mar 24, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 24, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 23, 2009ALIEASSIGNED TO LIE—
Mar 20, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 20, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 23, 2008GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 23, 2008GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 23, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 16, 2008DOCKASSIGNED TO EXAMINER—
Jul 23, 2008MPMKNOTICE OF PSEUDO MARK MAILED—
Jul 22, 2008NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance